Can you take Wegovy and Mounjaro together?

Combining weight loss medications increases risks and adverse side effects. Learn more about why it should be avoided.



When considering options for weight loss support, people often ask if weight loss medications like Wegovy and Mounjaro can be combined to enhance results.

The answer is simple: definitely not.

Yes, both medications are designed to support weight loss by affecting appetite, digestion and blood sugar regulation. However, the drugs work in similar ways and act on similar systems within the body. Taking them at the same time could significantly increase the risk of side effects and complications, with no clear evidence of additional benefit.

What's the difference between Wegovy and Mounjaro?

Wegovy and Mounjaro are prescription medications used to support weight loss and weight management.

Wegovy contains semaglutide, which mimics a hormone called 'glucagon-like peptide-1' (GLP-1). This hormone helps regulate appetite, slows stomach emptying and can help you feel fuller for longer.

Mounjaro contains tirzepatide, which works slightly differently. It targets both GLP-1 and another hormone called 'glucose-dependent insulinotropic polypeptide' (GIP). With this dual effect, it acts on multiple pathways involved in appetite and metabolism.

Although they are different medications, both ultimately work in similar ways.

Why shouldn't they be combined?

The biggest issue is that these medications affect similar systems in the body.

Both Wegovy and Mounjaro can:

• Reduce appetite 
• Slow digestion 
• Affect blood sugar regulation 
• Cause gastrointestinal side effects 
• Taking them together could intensify these effects beyond what is considered safe or tolerable.
• Some of the increased risks include:
• Severe nausea 
• Vomiting 
• Diarrhoea 
• Dehydration 
• Excessive appetite suppression 
• Increased risk of low blood sugar in some individuals 
  
  

There is currently no established clinical guidance recommending combined use for weight loss.

In other words, more medication does not mean better results.

Both medications are already highly effective when used alone and correctly alongside lifestyle support.

In clinical trials:

• Mounjaro users lost an average of around 21% of their starting body weight over 72 weeks.¹ 
• Wegovy users lost an average of around 15% over 68 weeks.²
  
  

These are significant results without any need to combine treatments.

For most patients, the safest and most effective approach is choosing the most appropriate medication for their individual needs. There's no need to combine multiple appetite-regulating drugs.

Why is medication interaction so important?

Whenever multiple medications affect similar systems in the body, there is potential for interactions or amplified side effects.

Some medications become dangerous if combined because they can:

Place extra strain on organs

Alter absorption or metabolism

Raise the risk of complications.

With GLP-1-based medications, the concern is not simply taking too much. It's also how strongly digestion, appetite and blood sugar pathways may be affected when treatments overlap.

Support from Semapen

The safest approach to a medically supported weight loss programme is working with a qualified clinical team. They can identify the right treatment and provide appropriate nutritional, behavioural and medical support.

Semapen is an NHS-trusted provider of weight management support. We pair expert medical oversight with personalised nutritional and behavioural support, giving you a comprehensive, safe and sustainable framework for long-term weight management.

If you're considering medically supported weight loss, why not explore our programmes or take our quick digital consultation to find out if you're eligible?

Sources

1. Jastreboff, A.M. et al. (2022) "Tirzepatide Once Weekly for the Treatment of Obesity" The New England Journal of Medicine, 387(3) https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J.P.H. et al. (2021) "Once-Weekly Semaglutide in Adults with Overweight or Obesity" The New England Journal of Medicine, 384(11) https://doi.org/10.1056/NEJMoa2032183

This article was reviewed and approved by Lujain Alhassan, Bariatric Nutritionist, on 1 June 2026.